References

  1. Alter MJ, Kruszon-Moran D, Nainan OV, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med. 1999;341:556-562.

  2. Prati D, Taioli E, Zanella A, et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med. 2002;137:1-10.

  3. Koff JM, Younossi Z, Reddy KR, Shiffman ML. Debate: hepatitis C with normal liver enzymes: to treat or not to treat. Am J Gastroenterol. 2004;99:972-976.

  4. Sarbah SA, Younossi ZM. Hepatitis C: an update on the silent epidemic. J Clin Gastroenterol. 2000;30:125-143.

  5. Younossi ZM. Viral hepatitis: guide for practicing physicians. Cleve Clin J Med. 2000;67(Suppl 1):S1-S48.

  6. Chronic Hepatitis C: Current Disease Management. Bethesda, MD: National Digestive Disease Information Clearinghouse; 2003. NIH publication no. 03-4230. Available at: http://digestive.niddk.nih.gov/ddiseases/pubs/chronic hepc/#B.

  7. National Center for Infectious Diseases, Centers for Disease Control and Prevention. Viral hepatitis C fact sheet. Available at: www.cdc.gov/ncidod/disease/hepatitis/c/fact.htm. Accessed September 20, 2004.

  8. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med. 2001;345:41-52.

  9. Williams I. Epidemiology of hepatitis C in the United States. Am J Med. 1999;107:2S-9S.

  10. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. Centers for Disease Control and Prevention. MMWR. Recomm Rep. 1998;47:1-39.

  11. Younossi ZM, Ong JP, O'Shea R. Contemporary Diagnosis and Management of Hepatitis C. Newton, PA: Handbooks in Health Care Company, 2003.

  12. Younossi ZM, McHutchison J. Serological tests for HCV infection. Viral Hepatitis Review. 1996;2:161-173.

  13. Pawlotsky JM, Lonjon I, Hezode C, et al. What strategy should be used for diagnosis of hepatitis C virus infection in clinical laboratories? Hepatology. 1998;27:1700-1702.

  14. Pawlotsky JM. Use and interpretation of virological tests for hepatitis C. Hepatology. 2002;36(Suppl 1):S65-S73.

  15. Thio CL, Nolt KR, Astemborski J, Vlahov D, Nelson KE, Thomas DL. Screening for hepatitis C virus in human immunodeficiency virus-infected individuals. J Clin Microbiol. 2000;38:575-577.

  16. Pawlotsky JM. Molecular diagnosis of viral hepatitis. Gastroenterology. 2002;122:1554-1568.

  17. Hadziyannis E, Hadziyannis A, Yen-Lieberman B, et al. Hepatitis C virus RNA assays: a comparison of SuperQuant and Monitor. J Clin Gastroenterol. 2001;33:45-48.

  18. Singer ME, Younossi ZM. Cost effectiveness of screening for hepatitis C virus in asymptomatic, average-risk adults. Am J Med. 2001;111:614-621.

  19. Saldanha J, Lelie N, Heath A. Establishment of the first international standard for nucleic acid amplification technology (NAT) assays for HCV RNA. WHO Collaborative Study Group. Vox Sang. 1999;76:149-158.

  20. Fang J, Chow V, Law J. HCV Infection: worldwide genotype distribution. Clin Liver Dis. 1997;1:503.

  21. National Institutes of Health Consensus Development Conference Panel statement: management of hepatitis C. Hepatology. 1997;26(Suppl 1):2S-10S.

  22. National Institutes of Health. National Institutes of Health Consensus Development Conference Statement: management of hepatitis C: 2002-June 10-12, 2002. Hepatology. 2002;36(Suppl 1):S3-S20.

  23. Walsh MJ, Vanags DM, Clouston AD, et al. Steatosis and liver cell apoptosis in chronic hepatitis C: a mechanism for increased liver injury. Hepatology. 2004;39:1230-1238.

  24. Knodell RG, Ishak KG, Black WC, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic hepatitis. Hepatology. 1981;1:431-435.

  25. Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol. 1995;22:696-699.

  26. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology. 1996;24:289-293.

  27. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. The French METAVIR Cooperative Study Group. Hepatology. 1994;20:15-20.

  28. McGill DB, Rakela J, Zinsmeister AR, Ott BJ. A 21-year experience with major hemorrhage after percutaneous liver biopsy. Gastroenterology. 1990;99:1396-1400.

  29. Cadranel JF, Rufat P, Degos F. Practices of liver biopsy in France: results of a prospective nationwide survey. For the Group of Epidemiology of the French Association for the Study of the Liver (AFEF). Hepatology. 2000;32:477-481.

  30. Muir AJ, Trotter JF. A survey of current liver biopsy practice patterns. J Clin Gastroenterol. 2002;35:86-88.
  31. Rey D, Carrieri MP, Spire B, et al. Factors associated with liver biopsy performance in HCV-HIV coinfected injecting drug users with HCV viremia: results from a five-year longitudinal assessment. J Urban Health. 2004;81:48-57.

  32. Maharaj B, Maharaj RJ, Leary WP, et al. Sampling variability and its influence on the diagnostic yield of percutaneous needle biopsy of the liver. Lancet.1986;1:523-525.

  33. Abdi W, Millan JC, Mezey E. Sampling variability on percutaneous liver biopsy. Arch Intern Med. 1979;139:667-669.

  34. Bedossa P, Dargere D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology. 2003;38:1449-1457.

  35. Poynard T, McHutchison J, Manns M, Myers RP, Albrecht J.
    Biochemical surrogate markers of liver fibrosis and activity in a randomized trial of peginterferon alfa-2b and ribavirin. Hepatology. 2003;38:481-492.

  36. Colloredo G, Guido M, Sonzogni A, Leandro G. Impact of liver biopsy size on histological evaluation of chronic viral hepatitis: the smaller the sample, the milder the disease. J Hepatol. 2003;39:239-244.

  37. Brunetti E, Silini E, Pistorio A, et al. Coarse vs. fine needle aspiration biopsy for the assessment of diffuse liver disease from hepatitis C virus-related chronic hepatitis. J Hepatol. 2004;40:501-506.

  38. Scheuer PJ. Liver biopsy size matters in chronic hepatitis: bigger is better. Hepatology. 2003;38:1356-1358.

  39. Andriulli A, Festa V, Leandro G, Rizzetto M. Usefulness of a liver biopsy in the evaluation of patients with elevated ALT values and serological markers of hepatitis viral infection: an AIGO study. Dig Dis Sci. 2001;46:1409-1415.

  40. Saadeh S, Cammell G, Carey WD, Younossi Z, Barnes D, Easley K. The role of liver biopsy in chronic hepatitis C. Hepatology. 2001;33:196-200.

  41. Bain VG, Bonacini M, Govindarajan S, et al. A multicentre study of the usefulness of liver biopsy in hepatitis C. J Viral Hepat. 2004;11:375-382.

  42. Dienstag JL. The role of liver biopsy in chronic hepatitis C. Hepatology. 2002;36 (Suppl 1):S152-S160.

  43. Imbert-Bismut F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, Poynard T; MULTIVIRC Group. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet. 2001;357:1069-1075.

  44. Wai CT, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. 2003;38:518-526.

  45. Heathcote EJ, Shiffman ML, Cooksley WG, et al. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med. 2000;343:1673-1680.

  46. Wiley TE, McCarthy M, Breidi L, McCarthy M, Layden TJ. Impact of alcohol on the histological and clinical progression of hepatitis C infection. Hepatology. 1998;28:805-809.

  47. Ostapowicz G, Watson KJ, Locarnini SA, Desmond PV. Role of alcohol in the progression of liver disease caused by hepatitis C virus infection. Hepatology. 1998;27:1730-1735.

  48. Monto A, Patel K, Bostrom A, et al. Risks of a range of alcohol intake on hepatitis C-related fibrosis. Hepatology. 2004;39:826-834.

  49. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358:958-965.

  50. Fried MW, Shiffman ML, Reddy R, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975-982.

  51. Lam NP, Neumann AU, Gretch DR, Wiley TE, Perelson AS, Layden TJ. Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa. Hepatology. 1997;26:226-231.

  52. Neumann AU, Lam NP, Dahari H, et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science. 1998;282:103-107.

  53. Zeuzem S, Herrmann E, Lee JH, et al. Viral kinetics in patients with chronic hepatitis C treated with standard or peginterferon alpha2a. Gastroenterology. 2001;120:1438-1447.

  54. Neumann AU, Lam NP, Dahari H, et al. Differences in viral dynamics between genotypes 1 and 2 of hepatitis C virus. J Infect Dis. 2000;182:28-35.

  55. Ribeiro RM, Layden-Almer J, Powers KA, Layden TJ, Perelson AS. Dynamics of alanine aminotransferase during hepatitis C virus treatment. Hepatology. 2003;38:509-517.

  56. Bergmann C, Layden JE, Levy-Drummer RS, Layden TJ, Haagmans BL, Neumann AU. Clinical implications of a new tri-phasic model of hepatitis C viral kinetics during IFN-alpha therapy [abstract]. Hepatology. 2001;33(Suppl):345A.

  57. Herrmann E, Lee JH, Marinos G, Modi M, Zeuzem S. Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon. Hepatology. 2003;37:1351-1358.

  58. Davis GL, Wong JB, McHutchison JG, Manns MP, Harvey J, Albrecht J. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology. 2003;38:645-652.

  59. Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. J Viral Hepat. 1999;6:35-47.

  60. Hoofnagle JH, Mullen KD, Jones DB, et al. Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon. A preliminary report. N Engl J Med.1986;315:1575-1578.

  61. Di Bisceglie AM, Martin P, Kassianides C, et al. Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. N Engl J Med. 1989;321:1506-1510.

  62. Davis GL, Balart LA, Schiff ER, et al. Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. Hepatitis Interventional Therapy Group. N Engl J Med. 1989;321:1501-1506.

  63. Carithers RL Jr, Emerson SS. Therapy of hepatitis C: meta-analysis of interferon alfa-2b trials. Hepatology. 1997;26(Suppl 1):83S-88S.

  64. Patterson JL, Fernandez-Larsson R. Molecular mechanisms of action of ribavirin. Rev Infect Dis. 1990;12:1139-1146.

  65. Dusheiko G, Main J, Thomas H, et al. Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study. J Hepatol. 1996;25:591-598.

  66. Schalm SW, Hansen BE, Chemello L, et al. Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C. Meta-analysis of individual patient data from European centers. J Hepatol. 1997;26:961-966.

  67. McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med.1998;339:1485-1492.

  68. Davis GL, Esteban-Mur R, Rustgi V, et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. N Engl J Med. 1998;339:1493-1499.

  69. Zeuzem S, Feinman SV, Rasenack J, et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med. 2000;343:1666-1672.

  70. Lindsay KL, Trepo C, Heintges T, et al. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology. 2001;34:395-403.

  71. Di Bisceglie AM, Hoofnagle JH. Optimal therapy of hepatitis C.
    Hepatology. 2002;36(5 Suppl 1):S121-127.

  72. EASL International Consensus Conference on Hepatitis C. Paris, 26-28, February 1999, Consensus Statement. European Association for the Study of the Liver. J Hepatol. 1999;30:956-961.

  73. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975-982.

  74. Shiffman ML. Retreatment of patients with chronic hepatitis C. Hepatology. 2002;36(Suppl 1):S128-S134.
  75. Shiffman ML, Di Bisceglie AM, Lindsay KL, et al, and the HALT-C Trial Group. Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology. 2004;126:1015-1023.

  76. Shiffman ML. Management options in nonresponders to previous HCV therapy. In: McHutchison JG, ed. Management Issues in Hepatitis C infection. London: Science Press; 2004:122-125.

  77. Kaiser S, Hass H, Gregor M. High viral response rates in previous interferon/ribavirin nonresponder patients with chronic hepatitis C retreated with consensus interferon induction therapy and ribavirin. Hepatology. 2002;36(4 Pt 2):358A. Abstract 779.

  78. Fried MW. Side effects of therapy of hepatitis C and their management. Hepatology. 2002;36(Suppl 1):S237-S244.

  79. McHutchison JG, Manns M, Patel K, et al. International Hepatitis Interventional Therapy Group. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology. 2002;123:1061-1069.

  80. Dieterich DT, Wasserman R, Brau N, et al. Once-weekly epoetin alfa improves anemia and facilitates maintenance of ribavirin dosing in hepatitis C virus-infected patients receiving ribavirin plus interferon alfa. Am J Gastroenterol. 2003; 98:2491-2499.
  81. Afdhal NH, Dieterich DT, Pockros PJ, et al. Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study. Gastroenterology. 2004;126:1302-1311.

  82. Van Thiel DH, Faruki H, Friedlander L, et al. Combination treatment of advanced HCV associated liver disease with interferon and G-CSF. Hepatogastroenterology. 1995;42:907-912.

  83. Shiffman ML, Hofmann CM, Luketic VA, Sanyal AJ. Use of granulocyte macrophage colony stimulating factor alone or in combination with interferon-alpha-2b for treatment of chronic hepatitis C. J Hepatol. 1998;28:382-389.

  84. Carreno V, Martin J, Pardo M, et al. Randomized controlled trial of recombinant human granulocyte-macrophage colony-stimulating factor for the treatment of chronic hepatitis C. Cytokine. 2000;12:165-170.
  85. Rustgi VK, Lee P, Finnegan S, Ershler W. Safety and efficacy of recombinant human IL-11 (oprelvekin) in combination with interferon/ribavirn in hepatitis C patients with thrombocytopenia [abstract]. Hepatology. 2002;36:361A.

  86. Wiley TE, Brown J, Chan J. Hepatitis C infection in African Americans: its natural history and histological progression. Am J Gastroenterol. 2002;97:700-706.

  87. Soza A, Everhart JE, Ghany MG, et al. Neutropenia during combination therapy of interferon alfa and ribavirin for chronic hepatitis C. Hepatology. 2002;36:1273-1279.
  88. Layden-Almer JE, Ribeiro RM, Wiley T, Perelson AS, Layden TJ. Viral dynamics and response differences in HCV-infected African American and white patients treated with IFN and ribavirin. Hepatology. 2003;37:1343-1350.

  89. Reddy KR, Hoofnagle JH, Tong MJ, et al. Racial differences in responses to therapy with interferon in chronic hepatitis C. Consensus Interferon Study Group. Hepatology. 1999;30:787-793.

  90. McHutchison JG, Poynard T, Pianko S, et al. The impact of interferon plus ribavirin on response to therapy in black patients with chronic hepatitis C. The International Hepatitis Interventional Therapy Group. Gastroenterology. 2000;119:1317-1323.

  91. Jeffers LJ, Cassidy W, Howell CD, Hu S, Reddy KR. Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1. Hepatology. 2004;39:1702-1708.

  92. Muir AJ, Bornstein JD, Killenberg PG; Atlantic Coast Hepatitis Treatment Group. Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N Engl J Med. 2004;350:2265-2271.

  93. Poynard T, McHutchison J, Manns M, et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology. 2002;122:1303-1313.

  94. Metwally MA, Zein CO, Zein NN. Regression of hepatic fibrosis and cirrhosis in patients with chronic hepatitis C treated with interferon-based therapy. Gastroenterology. 2003;124:1561.

  95. Shiffman ML, Di Bisceglie AM, Lindsay KL, et al. Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology. 2004;126:1015-1023.

  96. Crippin JS, McCashland T, Terrault N, Sheiner P, Charlton MR. A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation. Liver Transpl. 2002;8:350-355.

  97. Thomas RM, Brems JJ, Guzman-Hartman G, Yong S, Cavaliere P, Van Thiel DH. Infection with chronic hepatitis C virus and liver transplantation: a role for interferon therapy before transplantation. Liver Transpl. 2003;9:905-915.

  98. Everson GT, Trotter JF, Kugelmas M. Long-term outcome of patients with chronic hepatitis C and decompensated liver disease treated with the LADR protocol (low-accelerating-dose regimen) [abstract]. Hepatology. 2002;36:297A.

  99. Berenguer M. Natural history of recurrent hepatitis C. Liver Transpl. 2002;8(Suppl 1):S14-S18.

  100. Forman LM, Lewis JD, Berlin JA, Feldman HI, Lucey MR. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology. 2002;122:889-896.

  101. Gane EJ, Portmann BC, Naoumov NV, et al. Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med. 1996;334:815-820.

  102. Baltz AC, Trotter JF. Living donor liver transplantation and hepatitis C. Clin Liver Dis. 2003;7:651-665.

  103. Russo MW, Galanko J, Beavers K, Fried MW, Shresta R. Patient and graft survival in hepatitis C recipients after adult living donor liver transplantation in the United States. Liver Transpl. 2004;10:340-346.

  104. Forman LM, Trotter JF, Emond J. Living donor liver transplantation and hepatitis C. Liver Transpl. 2004;10:347-348.

  105. Wright TL, Combs C, Kim M, et al. Interferon-alpha therapy for hepatitis C virus infection after liver transplantation. Hepatology. 1994;20:773-779.

  106. Feray C, Samuel D, Gigou M, et al. An open trial of interferon alfa recombinant for hepatitis C after liver transplantation: antiviral effects and risk of rejection. Hepatology. 1995;22:1084-1089.

  107. Gane EJ, Lo SK, Riordan SM, et al. A randomized study comparing ribavirin and interferon alfa monotherapy for hepatitis C recurrence after liver transplantation. Hepatology.1998;27:1403-1407.

  108. Narayanan Menon KV, Poterucha JJ, El-Amin OM, et al. Treatment of posttransplantation recurrence of hepatitis C with interferon and ribavirin: lessons on tolerability and efficacy. Liver Transpl. 2002;8:623-629.

  109. Firpi RJ, Abdelmalek MF, Soldevila-Pico C, et al. Combination of interferon alfa-2b and ribavirin in liver transplant recipients with histological recurrent hepatitis C. Liver Transpl. 2002;8:1000-1006.

  110. Gopal DV, Rabkin JM, Berk BS, et al. Treatment of progressive hepatitis C recurrence after liver transplantation with combination interferon plus ribavirin. Liver Transpl. 2001;7:181-190.

  111. Kennedy C, McClure M, Brackett T, Fernandes B, Steinberg T, Kugelmas M. Achieving EVR in post-liver transplant patients with chronic hepatitis C: is it a fair goal of therapy? [abstract] Am J Transpl. 2004;4(Suppl 8):A1234.

  112. Abdelmalek MF, Firpi RJ, Soldevila-Pico C, et al. Sustained viral response to interferon and ribavirin in liver transplant recipients with recurrent hepatitis C. Liver Transpl. 2004;10:199-207.

  113. Sheiner PA, Boros P, Klion FM, et al. The efficacy of prophylactic interferon alfa-2b in preventing recurrent hepatitis C after liver transplantation. Hepatology. 1998;28:831-838.

  114. Everson GT. Impact of immunosuppressive therapy on recurrence of hepatitis C. Liver Transpl. 2002;8(Suppl 1):S19-S27.

  115. Zekry A, Gleeson M, Guney S, McCoughan GW. A prospective cross-over study comparing the effect of mycophenolate versus azathioprine on allograft function and viral load in liver transplant recipients with recurrent chronic HCV infection. Liver Transpl. 2004;10:52-57.

  116. Kugelmas M, Osgood MJ, Trotter JF, et al. Hepatitis C virus therapy, hepatocyte drug metabolism, and risk for acute cellular rejection. Liver Transpl. 2003;9:1159-1165.

  117. Stravitz RT, Shiffman ML, Sanyal AJ, et al. Effects of interferon treatment on liver histology and allograft rejection in patients with recurrent hepatitis C following liver transplantation. Liver Transpl. 2004;10:850-858.

  118. Saab S, Kalmaz D, Gajjar NA, et al. Outcomes of acute rejection after interferon therapy in liver transplant recipients. Liver Transpl. 2004;10:859-867.

  119. Thomas DL. Hepatitis C and human immunodeficiency virus infection. Hepatology. 2002;36(Suppl 1):S201-S209.

  120. Graham CS, Baden LR, Yu E, et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis. 2001;33:562-569.

  121. Eyster ME, Diamondstone LS, Lien JM, Ehmann WC, Quan S, Goedert JJ. Natural history of hepatitis C virus infection in multitransfused hemophiliacs: effect of coinfection with human immunodeficiency virus. The Multicenter Hemophilia Cohort Study. J Acquir Immune Defic Syndr. 1993;6:602-610.

  122. Sulkowski MS, Thomas DL. Hepatitis C in the HIV-infected person. Ann Intern Med. 2003;138:197-207.

  123. Martagon J, Gordon SM. Special management challenges in hepatitis C. Cleve Clin J Med. 2003;70(Suppl 4):S27-S33.

  124. Soriano V, Garcia-Samaniego J, Bravo R, et al. Interferon alpha for the treatment of chronic hepatitis C in patients infected with human immunodeficiency virus. Hepatitis-HIV Spanish Study Group. Clin Infect Dis. 1996;23:585-591.

  125. Perez-Olmeda M, Nunez M, Romero M, et al. Pegylated IFN-alpha2b plus ribavirin as therapy for chronic hepatitis C in HIV-infected patients. AIDS. 2003;17:1023-1028.

  126. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med. 2004;351:438-450.

  127. Chung RT, Andersen J, Volderbing P, et al. Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med. 2004;351:451-459.

  128. Sulkowski MS, Thomas DL, Chaisson RE, Moore RD. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA. 2000;283:74-80.

  129. Chin CF, Zein NN. Extrahepatic syndromes associated with hepatitis C infection. Gastroenterology International. 1998;11:26-35.

  130. Fabrizi F, Poordad FF, Martin P. Hepatitis C infection and the patient with end-stage renal disease. Hepatology. 2002;36:3-10.

  131. Huang CC. Hepatitis in patients with end-stage renal disease. J Gastroenterol Hepatol. 1997;12:S236-S241.

  132. Carithers RL Jr. Hepatitis C and renal failure. Am J Med. 1999;107(6B):90S-94S.

  133. Daghestani L, Pomeroy C. Renal manifestations of hepatitis C infection. Am J Med. 1999;106:347-354.

  134. Stehman-Breen CO, Emerson S, Gretch D, Johnson RJ. Risk of death among chronic dialysis patients infected with hepatitis C virus. Am J Kidney Dis. 1998;32:629-634.

  135. Furusyo N, Hayashi J, Kanamoto-Tanaka Y, et al. Liver damage in hemodialysis patients with hepatitis C virus viremia: a prospective 10-year study. Dig Dis Sci. 2000;45:2221-2228.

  136. Sterling RK, Sanyal AJ, Luketic VA, et al. Chronic hepatitis C infection in patients with end stage renal disease: characterization of liver histology and viral load in patients awaiting renal transplantation. Am J Gastroenterol. 1999;94:3576-3582.

  137. Magrin S, Craxi A, Fabiano C, et al. Hepatitis C viremia in chronic liver disease: relationship to interferon-alpha or corticosteroid treatment. Hepatology. 1994;19:273-279.

  138. Misiani R, Bellavita P, Fenili D, et al. Interferon alfa-2a therapy in cryoglobulinemia associated with hepatitis C virus. N Engl J Med. 1994;330:751-756.

  139. Tan AC, Brouwer JT, Glue P, et al. Safety of interferon and ribavirin therapy in haemodialysis patients with chronic hepatitis C: results of a pilot study. Nephrol Dial Transplant. 2001;16:193-195.

  140. Fernandez JL, Rendo P, del Pino N, Viola L. A double-blind controlled trial of recombinant interferon-alpha 2b in haemodialysis patients with chronic hepatitis C virus infection and abnormal aminotransferase levels. Nephrologists' Group for the Study of HCV infection. J Viral Hepat. 1997;4:113-119.

  141. Campistol JM, Esforzado N, Martinez J, et al. Efficacy and tolerance of interferon-alpha(2b) in the treatment of chronic hepatitis C virus infection in haemodialysis patients. Pre- and post-renal transplantation assessment. Nephrol Dial Transplant. 1999;14:2704-2709.

  142. Degos F, Pol S, Chaix ML, et al. The tolerance and efficacy of interferon-alpha in haemodialysis patients with HCV infection: a multicentre, prospective study. Nephrol Dial Transplant. 2001;16:1017-1023.

  143. Izopet J, Rostaing L, Sandres K, et al. Longitudinal analysis of hepatitis C virus replication and liver fibrosis progression in renal transplant recipients. J Infect Dis. 2000;181:852-858.

  144. Hanafusa T, Ichikawa Y, Kishikawa H, et al. Retrospective study on the impact of hepatitis C virus infection on kidney transplant patients over 20 years. Transplantation. 1998;66:471-476.

  145. Knoll GA, Tankersley MR, Lee JY, Julian BA, Curtis JJ. The impact of renal transplantation on survival in hepatitis C-positive end-stage renal disease patients. Am J Kidney Dis. 1997;29:608-614.

  146. Periera BJ, Wright TL, Schmid CH, Levey AS. The impact of pretransplantation hepatitis C infection on the outcome of renal transplantation. Transplantation. 1995;60:799-805.

  147. Tokumoto T, Tanabe K, Ishikawa N, et al. Effect of interferon-alpha treatment in hemodialysis patients and renal transplant recipients with chronic hepatitis C. Transplant Proc. 1999;31:2887-2889.

  148. Alter MJ. Prevention of spread of hepatitis C. Hepatology. 2002;36(Suppl 1):S93-S98.

  149. Davis GL, Rodrigue JR. Treatment of chronic hepatitis C in active drug users. N Engl J Med. 2001;345:215-217.

  150. Edlin BR, Seal KH, Lorvick J, et al. Is it justifiable to withhold treatment for hepatitis C from illicit-drug users? N Engl J Med. 2001;345:211-215.

  151. Ong J, Younossi Z, Speer C, Olano A, Gramlich T, Boparai N. Chronic hepatitis C and superimposed nonalcoholic fatty liver disease. Liver. 2001;21:266-271.

  152. Younossi Z, McCullough A, Ong J, et al. Obesity and non-alcoholic fatty liver disease in chronic hepatitis C. J Clin Gastroenterol. 2004;38:705-709.

  153. Poynard T, Ratziu V, McHutchison J, et al. Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology. 2003;38:75-85.

  154. Bressler BL, Guindi M, Tomlinson G, Heathcote J. High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C. Hepatology. 2003;38:639-644.

  155. Lam NP, Pitrak D, Speralakis R, Lau AH, Wiley TE, Layden TJ. Effect of obesity on pharmacokinetics and biologic effect of interferon-alpha in hepatitis C. Dig Dis Sci. 1997;42:178-185.

  156. Hickman IJ, Clouston AD, Macdonald GA, et al. Effect of weight reduction on liver histology and biochemistry in patients with chronic hepatitis C. Gut. 2002;51:89-94.

  157. McCullough A. Obesity and its nurturing effect on hepatitis C. Hepatology. 2003; 38:557-559.

  158. Wedemeyer H, Tegtmeyer B, Tillmann HL, et al. Impact of HBV coinfection on hepatitis C virus infection: analysis of 3,054 anti HCV-positive patients [abstract]. J Hepatol. 2001;34(Suppl 1):4-5.

  159. Weltman MD, Brotodihardjo A, Crewe EB, et al. Coinfection with hepatitis B and C or B, C and delta viruses results in severe chronic liver disease and responds poorly to interferon-alpha treatment. J Viral Hepat. 1995;2:39-45.

  160. Chiaramonte M, Stroffolini T, Vian A, et al. Rate of incidence of hepatocellular carcinoma in patients with compensated viral cirrhosis. Cancer. 1999;85:2132-2137.

  161. Sagnelli E, Coppola N, Scolastico C, Mogavero AR, Filippini P, Piccinino F. HCV genotype and "silent" HBV coinfection: two main risk factors for a more severe liver disease. J Med Virol. 2001;64:350-355.

  162. Koike K, Nakamura Y, Kobayashi M, et al. Hepatitis B virus DNA integration frequently observed in the hepatocellular carcinoma DNA of the hepatitis C virus-infected patients. Int J Oncol. 1996;8:781-784.

  163. Lau G, Piratvisuth T, Luo KX, et al. Peginterferon alfa-2a (40 kd) (Pegasys) monotherapy and in combination with lamivudine is more effective than lamivudine monotherapy in HBeAg-positive chronic hepatitis B: results from a large, multinational study [abstract]. Hepatology. 2004;40(Suppl 1):171A. Abstract 20.

  164. Marcellin P, Levy S, Erlinger S. Therapy of hepatitis C: patients with normal aminotransferase levels. Hepatology. 1997;26(Suppl 1):133S-136S.

  165. Zeuzem S, Diago M, Gane E, et al. International, multicenter, randomized, controlled study for the treatment of patients with chronic hepatitis C and persistently normal ALT levels with peginterferon alfa-2a and ribavirin [abstract]. Hepatology. 2003;38(Suppl):208A.

  166. Hepatitis C virus infection. American Academy of Pediatrics. Committee on Infectious Diseases. Pediatrics. 1998;101:481-485.

  167. American Academy of Pediatrics. Hepatitis C. In: Peter G, ed. Red Book: 1997 Report of the Committee on Infectious Diseases. Elk Grove Village, IL: American Academy of Pediatrics; 1997:260-264.

  168. Bortolotti F, Giacchino R, Vajro P, et al. Recombinant interferon-alfa therapy in children with chronic hepatitis C. Hepatology. 1995; 22:1623-1627.

  169. Matsuoka S, Mori K, Nakano O, et al. Efficacy of interferons in treating children with chronic hepatitis C. Eur J Pediatr. 1997;156:704-708.

  170. McDiarmid SV, Conrad A, Ament ME, et al. De novo hepatitis C in children after liver transplantation. Transplantation. 1998;66:311-318.

  171. Beltrami EM, Williams IT, Shapiro CN, Chamberland ME. Risk and management of blood-borne infections in health care workers. Clin Microbiol Rev. 2000;13:385-407.

  172. Puro V, Petrosillo N, Ippolito G. Risk of hepatitis C seroconversion after occupational exposures in health care workers. Italian Study Group on Occupational Risk of HIV and Other Bloodborne Infections. Am J Infect Control. 1995;23:273-277.

  173. Updated U.S. Public Health Service guidelines for the management of occupational exposures to HBV, HCV, and HIV and recommendations for postexposure prophylaxis. MMWR Recomm Rep. 2001;50(RR-11):1-52.

  174. Hoofnagle JH. Hepatitis C: the clinical spectrum of disease. Hepatology. 1997;26(Suppl 1):15S-20S.

  175. Centers for Disease Control and Prevention. Recommendations for follow-up of health-care workers after occupational exposures to hepatitis C virus. MMWR Morb Mortal Wkly Rep. 1997;46:603-606.

  176. Alter MJ. Occupational exposure to hepatitis C virus: a dilemma. Infect Control Hosp Epidemiol. 1994;15:742-744.

  177. American College of Surgeons. Statement on the surgeon and hepatitis [ST-22]. April 2004. Available at: www.facs.org/fellows_info/statements/st-22.html. Accessed September 2, 2004.

  178. Centers for Disease Control and Prevention. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR Recomm Rep. 1998;47(RR-19):1-39.

  179. Gerlach JT, Diepolder HM, Zachoval R, et al. Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance. Gastroenterology. 2003;125:80-88.

  180. Hoofnagle JH. Course and outcome of hepatitis C. Hepatology. 2002;36(Suppl 1):S21-S29.

  181. Jaeckel E, Cornberg M, Wedemeyer H, et al; German Acute Hepatitis C Therapy Group. Treatment of acute hepatitis C with interferon alfa-2b. N Engl J Med. 2001;345:1452-1457.

  182. Bosch FX. Global epidemiology of hepatocellular carcinoma. In: Osuda K, Tabor E (eds). Liver Cancer. New York, NY: Churchill Livingston; 1997:13-28.

  183. Di Bisceglie AM. Malignant tumors of the liver. In: Schiff ER, Sorrell MF, Maddrey WC (eds). Schiff's Diseases of the Liver. 8th ed. Philadelphia: Lippincott-Raven; 1999:1281-1304.

  184. El-Serag HB. Hepatocellular carcinoma and hepatitis C in the United States. Hepatology. 2002;36(5 Suppl 1):S74-S83.

  185. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med. 1999;340:745-750.

  186. Colombo M. Natural history and pathogenesis of hepatitis C virus related hepatocellular carcinoma. J Hepatol. 1999;31(Suppl 1):25-30.

  187. Okuda K. Hepatocellular carcinoma. J Hepatol. 2000;32(Suppl):225-237.

  188. El-Serag HB. Epidemiology of hepatocellular carcinoma. Clin Liver Dis. 2001;5:87-107.

  189. De Mitri MS, Poussin K, Baccarini P, et al. HCV-associated liver cancer without cirrhosis. Lancet. 1995;345:413-415.

  190. Colombo M. Hepatitis C virus and hepatocellular carcinoma. Semin Liver Dis. 1999;19:263-269.

  191. Sherman M. Screening for hepatocellular carcinoma. Baillieres Best Pract Res Clin Gastroenterol.1999;13:623-635.

  192. Gebo KA, Chander G, Jenckes MW, et al. Screening tests for hepatocellular carcinoma in patients with chronic hepatitis C: a systematic review. Hepatology. 2002;36 (Suppl 1):S84-S92.

  193. El-Serag HB, Mason AC. Risk factors for the rising rates of primary liver cancer in the United States. Arch Intern Med. 2000;160:3227-3230.

  194. Liang TJ, Jeffers LJ, Reddy KR, et al. Viral pathogenesis of hepatocellular carcinoma in the United States. Hepatology. 1993;18:1326-1333.

  195. Garcia-Samaniego J, Rodriguez M, Berenguer J, et al. Hepatocellular carcinoma in HIV-infected patients with chronic hepatitis C. Am J Gastroenterol. 2001;96:179-183.

  196. Bruix J, Sherman M, Llovet JM, et al. EASL Panel of Experts on HCC. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol. 2001;35:421-430.

  197. Gupta S, Bent S, Kohlwes J. Test characteristics of alpha-fetoprotein for detecting hepatocellular carcinoma in patients with hepatitis C. A systematic review and critical analysis. Ann Intern Med. 2003;139:46-50.

  198. Ishiguchi T, Shimamoto K, Fukatsu H, et al. Radiologic diagnosis of hepatocellular carcinoma. Semin Surg Oncol. 1996;12:164-169.

  199. Larcos G, Sorokopud H, Berry G, Farrell GC. Sonographic screening for hepatocellular carcinoma in patients with chronic hepatitis or cirrhosis: an evaluation. AJR Am J Roentgenol.1998;171:433-435.

  200. Hollett MD, Jeffrey RB Jr, Nino-Murcia M, et al. Dual-phase helical CT of the liver: value of arterial phase scans in the detection of small (< or = 1.5 cm) malignant hepatic neoplasms. AJR Am J Roentgenol. 1995;164:879-884.

  201. Lim JH, Choi D, Kim SH, et al. Detection of hepatocellular carcinoma: value of adding delayed phase imaging to dual-phase helical CT. AJR Am J Roentgenol. 2002;179:67-73.

  202. Ngan H. Lipiodol computerized tomography: how sensitive and specific is the technique in the diagnosis of hepatocellular carcinoma? Br J Radiol. 1990;63:771-775.

  203. Singh N, Gayowski T, Wagener MM, Marino IR. Vulnerability to psychologic distress and depression in patients with end-stage liver disease due to hepatitis C virus. Clin Transplant.1997;11:406-411.

  204. Malaguarnera M, Di Fazio I, Restuccia S, Pistone G, Ferlito L, Rampello L. Interferon alpha-induced depression in chronic hepatitis C patients: comparison between different types of interferon alpha. Neuropsychobiology. 1998;37:93-97.

  205. Goulding C, O'Connell P, Murray FE. Prevalence of fibromyalgia, anxiety and depression in chronic hepatitis C virus infection: relationship to RT-PCR status and mode of acquisition. Eur J Gastroenterol Hepatol. 2001;13:507-511.

  206. Yates WR, Gleason O. Hepatitis C and depression. Depress Anxiety. 1998;7:188-193.

  207. Johnson ME, Fisher DG, Fenaughty A, Theno SA. Hepatitis C virus and depression in drug users. Am J Gastroenterol. 1998;93:785-789.

  208. McDermott BE, Sautter FJ Jr, Winstead DK, Quirk T. Diagnosis, health beliefs, and risk of HIV infection in psychiatric patients. Hosp Community Psychiatry. 1994;45:580-585.

  209. Pariante CM, Orru MG, Baita A, Farci MG, Carpiniello B. Treatment with interferon-alpha in patients with chronic hepatitis and mood or anxiety disorders. Lancet. 1999;354:131-132.

  210. Renault PF, Hoofnagle JH, Park Y, et al. Psychiatric complications of long-term interferon alfa therapy. Arch Intern Med. 1987;147:1577-1580.

  211. Lee DH, Jamal H, Regenstein FG, Perrillo RP. Morbidity of chronic hepatitis C as seen in a tertiary care medical center. Dig Dis Sci. 1997;42:186-191.

  212. Miyaoka H, Otsubo T, Kamijima K, Ishii M, Onuki M, Mitamura K. Depression from interferon therapy in patients with hepatitis C. Am J Psychiatry. 1999;156:1120.

  213. Schaefer M, Schmidt F, Folwaczny C, et al. Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups. Hepatology. 2003;37:443-451.

  214. Flamm SL, Mendenhall C, Johnson D, et al. Psychosocial discord underlies poor adherence to antiviral therapy in the VA population: results of a demographic survey of the VA population undergoing HCV therapy. Hepatology. 2003;38(4 suppl 1):326A-327A. Abstract 346.

  215. Carlat DJ. The psychiatric review of symptoms: a screening tool for family physicians. Am Fam Physician. 1998;58:1617-1624.

  216. Pignone MP, Gaynes BN, Rushton JL, et al. Screening for depression in adults: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2002;136:765-776.

  217. Loftis JM, Socherman RE, Howell CD, et al. Association of interferon-alpha-induced depression and improved treatment response in patients with hepatitis C. Neurosci Lett. 2004;365:87-91.

  218. Hauser P, Khosla J, Aurora H, et al. A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C. Mol Psychiatry. 2002;7:942-947.

  219. Raison CL, Borisov AS, Broadwell SD, et al. Depression during IFN-alfa plus ribavirin therapy: prevalence and prediction. Hepatology. 2003;38(4 suppl 1):326A. Abstract 345.

  220. Hauser P, Soler R, Reed S, et al. Prophylactic treatment of depression induced by interferon-alpha. Psychosomatics. 2000;41:439-441.

  221. Musselman DL, Lawson DH, Gumnick JF, et al. Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Med. 2001;344:961-966.

  222. Schaefer M, Schwaiger M, Berg T. Citalopram for prevention of interferon-alpha associated depression in psychiatric risk patients. Hepatology. 2003;38(4 suppl 1):320A. Abstract 333.

  223. Van Thiel DH, Anantharaju A, Creech S. Response to treatment of hepatitis C in individuals with a recent history of intravenous drug abuse. Am J Gastroenterol. 2003;98:2281-2288.

  224. Mauss S, Berger F, Goelz J, Jacob B, Schmutz G. A prospective controlled study of interferon-based therapy of chronic hepatitis C in patients on methadone maintenance. Hepatology. 2004;40:120-124.

  225. Falck-Ytter Y, Kale H, Mullen KD, Sarbah S, Sorescu L, McCullough AJ. Surprisingly small effect of antiviral treatment in patients with hepatitis C. Ann Intern Med. 2002;136:288-292.

  226. Gish R, Arora S, Nelson D, Fernandez H, Lamon K. Safety and efficacy of viramidine in combination with pegylated interferon alfa-2a for treatment of hepatitis C in therapy-naïve patients. Presented at: 39th Annual Meeting of the European Association for the Study of the Liver; April 17, 2004; Berlin, Germany.

  227. Hinrichsen H, Benhamou Y, Wedemeyer H, et al. Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients. Gastroenterology. 2004;127:1347-1355.

  228. Godofsky E, et al. Phase I/II dose escalation trial assessing tolerance, pharmacokinetics, and antiviral activity of NM283, a novel antiviral treatment for hepatitis C [abstract]. Presented at: Digestive Disease Week; May 18, 2004; New Orleans, LA. Abstract 407.